Management of Dualsystems Biotech AG


Dr. Paul Helbling



Dr. Paul Helbling CEO studied biology at the University of Zürich and obtained his PhD in developmental biology at the Swiss Federal Institute of Technology (ETH) in Zurich. After the PhD he worked at the Foundation for Cardiovascular Research and organized clinical studies according to GCP. He moved on to MDS Pharma Services where he held various positions in the GLP compliant facilities and was at the end responsible for the ligand binding group that was specialized in the analysis of biologics and anti-drug antibodies. In a next step, he was working in business development at the GMP compliant facilities of Solvias AG, responsible for southern Europe and Germany and opening new market territories in Turkey. Then he became Head of Business Development at IBR Inc., Institute for Biopharmaceutical Research a GLP compliant service provider specialized in cell based assays before he joined the Team of Dualsystems.
Paul Helbling is fully responsible for the management of Dualsystems and reports into the board of directors.



Board of Directors of Dualsystems Biotech AG

Dr. Raymond Bisang, President

Dr. Raymond Bisang, PresidentRaymond Bisang is a co-founder of Dualsystems. He is a senior partner of the law firm Suhr Würgler Maag Bisang in Zürich. He graduated from the University of Zürich and used to be a district judge before he changed 1987 to practice as attorney at law. Besides the occupation within his law firm and Dualsystems, he holds board positions in a number of other companies in the fields of life science and finance.

Professor Dr. Michael Hottiger, Vice President

Professor Dr. Michael Hottiger, Vice PresidentMichael O. Hottiger (Prof. et phil.II) is a co-founder of Dualsystems Biotech AG. He is a full professor for Molecular Biology at the Institute of Veterinary Biochemistry and Molecular Biology at the University of Zurich.
He studied Veterinary Medicine and Molecular Biology (University of Zurich). He then moved to the Howard Hughes Medical Institute at the University of Michigan (Ann Arbor, USA) before accepting a position as principal investigator at the University of Zurich in 1998. In 2001 he received the Dr. Ernst Th. Jucker Award and in 2004 the PHOENIX Pharmazie-Wissenschaftspreis. The research in Michael’s group is focused on the molecular mechanisms of NF-kappaB-dependent gene expression during inflammation.

Dr. Jan zur Hausen

Dr. Jan zur Hausen

Jan zur Hausen joined Dualsystems’ board of directors in 2010. He is a Managing Director of Bergmann zur Hausen & Cie. GmbH, a corporate finance firm specializing in the healthcare industry. Previously he was Senior Vice President and Head of Healthcare Investment Banking at Sal. Oppenheim jr. & Cie. KGaA. Before, he was a Partner in the Life Science Team of DVC (Deutsche Venture Capital) and heretofore a member of the executive board of Mulligan BioCapital AG, where he was responsible for building and managing a portfolio of European and US life science companies.
His curriculum also includes positions at MPM Capital, a US based venture capital firm and at Hoffmann-La Roche in Basel and Nutley, NJ.
Jan did his undergraduate work at the University of Hohenheim and received a Ph.D. from the University of Basel.